BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 2
• 3
• 4
• 5
• 6
• 7

• 

  Business

  Basel Life Sciences Scene Embraces International Companies, Startups

  The Basel area is home to over 800 life sciences companies, including Novartis and Roche, according to nonprofit Basel Area Business & Innovation. The nonprofit’s CEO and a BeOne Medicines executive discuss the location’s evolution, advantages and future.

  November 6, 2025

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Regulatory

  ‘Chaotic’ HHS Overhaul a Wrecking Ball Toward a Better FDA: Former CIO

  The upheaval of the Health and Human Services workforce and leadership leaves much to be desired in terms of delivery, recently retired FDA Chief Information Officer Vid Desai tells BioSpace, but the regulatory agency is evolving to be more open to much needed change.

  November 6, 2025

   · 

  5 min read

   · 

  Jef Akst
• 

  Radiopharmaceuticals

  Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed

  While investment has slowed in radiopharmaceuticals, analysts predict increased interest to come as Novartis shows just how successful radiopharmaceuticals can be.

  November 6, 2025

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  FDA

  FDA’s Top Cancer Regulator Declined CDER Directorship

  The search continues for a new leader for the FDA’s Center for Drug Evaluation and Research after George Tidmarsh resigned on Sunday. Deputy Director Mike Davis is in the running, along with Mary Thanh Hai, currently head of the Office of New Drugs.

  November 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  AstraZeneca Builds Obesity Pipeline On ‘Medical Aspect,’ Not Aesthetics

  In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based on “the medical aspect” of weight loss, including driving down visceral fat.

  November 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  IN PARTNERSHIP WITH PII

  Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience

  In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of technological burden to improve compliance with guests Oliver Eden and Travis Webb.

  November 6, 2025

   · 

  1 min read

   · 

  BioSpace Insights
• 

  Earnings

  Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing

  The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting campaign is helping to stem the downward trend.

  November 6, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Obesity

  Novo’s Metsera Bid Attracts FTC Scrutiny as Pfizer Matches $10B Offer

  Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera. The antitrust watchdog has spotted issues with the structure of Novo’s bid, while its New York-based rival has put more money on the table.

  November 6, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Legal

  Delaware Court Denies Pfizer’s Bid To Block Novo-Metsera Deal

  The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk’s higher bid.

  November 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Obesity

  Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss

  The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.

  November 6, 2025

   · 

  3 min read

   · 

  Heather McKenzie